Background: MicroRNAs (miRNAs) are short non-coding segments of RNA which
Introduction
Colorectal cancer is the third most common cancer worldwide and second only to lung cancer as the leading cause of death from cancer in Western countries. 1 Currently, the only curative treatment is surgical resection, with modest survival benefit from chemotherapy, particularly in Stage III disease. 2 The majority of patients who develop colorectal cancer have no specific risk factor for the disease and the best indicator of prognosis is stage at diagnosis. Therefore, early detection is crucial and new diagnostic markers are needed to identify disease at an earlier stage.
MicroRNAs
MicroRNAs (miRNAs) are small (19-25 ribonucleotides) , single-stranded non-coding
RNAs encoded in plant, invertebrate and vertebrate genomes. 3 They regulate gene expression at post-transcriptional level by acting on specific messenger RNA (mRNA) targets, inducing mRNA degradation or translational inhibition. 4 5 MiRNAs are involved in regulation of pathways in cell differentiation, cell cycle progression and apoptosis. 4 Each miRNA is assigned a numerical identifier and more than 900 have been identified in humans to date. 6 
MiRNAs and cancer
MiRNAs were first linked with cancer in 2002, initially chronic lymphocytic leukaemia (CLL), and subsequently many other types including colorectal cancer. 3 7-9 Expression of miRNAs is dysregulated (either overexpressed or silenced) in malignancy, with some thought to behave as tumour suppressor genes and others as oncogenes. Dysregulation of miRNA expression may therefore contribute to development of cancer through loss of these controls and miRNA expression M A N U S C R I P T
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3 represents a means to detect or characterise specific cancers. Thus miRNA expression levels may have potential for use as biomarkers of tumour presence or activity.
MiRNA biochemistry
MiRNAs are the product of miRNA genes (found as independent transcripts or within introns of another gene). They are transcribed in the nucleus by RNA polymerase II as primary transcripts (pri-miRNAs), processed by an RNA specific ribonuclease enzyme complex (DROSHA) into short 70 nucleotide precursor-miRNAs (premiRNAs), and transported to the cytoplasm by exportin 5. In the cytoplasm premiRNAs are further cleaved by the endonuclease, Dicer, generating mature miRNAs.
10-12
Mature miRNAs do not code for proteins but regulate protein production in the cell by binding to complementary 'target' mRNAs via the RNA-induced silencing complex (RISC). [12] [13] [14] With perfect pairing to target mRNAs, this complex inhibits protein expression by cleavage and degradation of mRNA. 10 15 MiRNAs can also bind to imperfect complementary sites within the 3'untranslated regions (3'UTR) of mRNA targets and act through translational inhibition of gene expression. 10 11 MiRNAs may also interfere with protein translation in polyribosomes.
Regardless of the mechanism employed, the final effect is reduction of protein production by genes regulated by that miRNA. 20 21 Most studies on miRNAs in colorectal cancer focus on miRNA expression in human or murine tissues or human colon cancer cell lines. However, recent advances have shown that they are also present and detectable in circulation. Circulating miRNAs appear to be stable and resistant to degradation by endogenous ribonucleases. and miR-618 binding sites) genes and colorectal cancer risk. 25 However, a recent
Korean study of 426 patients with adenocarcinoma invesitgated 40miRNA-related gene polymorphisms and found none to be an independent prognostic marker in this cohort. 
Role in disease progression, invasion & metastases
In addition to initiation of tumorigenesis, dysregulated miRNAs may have a role in disease progression through promotion of growth, invasion and metastasis.
Involvement of miRNAs in metastasis was first reported in breast cancer by Ma et al.
in 2007, who showed that miR-10b initiates breast cancer invasion and metatasis. 28 Lujambio et al. subsequently identified a miRNA hypermethylation profile characteristic of human metastasis (including colorectal cancer) which suggested that DNA methylation-associated silencing of tumour suppressor miRNAs contributes to the development of human cancer metastasis. 29 In this study, which used colorectal cancer (SW620), melanoma (IGR37) and head and neck cancer (SIHN-011B) cell lines derived from lymph node metastases, reintroduction of miR-148a, miR-34b and 
miR-34c into cancer cells with epigenetic inactivation inhibited motility, tumour
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Microsatellite instability
Microsatellite instability is indicative of defective DNA mismatch repair and, in colorectal tumours, is associated with a poor response to chemotherapy but an overall better prognosis. 32 MiRNA expression profiles may allow high-microsatellite instability tumours to be distinguished from microsatellite stable tumours. [33] [34] [35] MiRNA profiles appear to separate microsatellite unstable colorectal cancer from microsatellite stable cancer with a specificity of around 80% and sensitivity of around 90%, and may be partly responsible for their differing clinical behaviour. 33 34 M A N U S C R I P T
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MiRNAs in circulation
Although there are fewer published studies on circulating miRNA profiles, they appear to reflect tissue expression, and hence are altered in malignancy. This has been shown in several cancer types including prostate cancer and breast cancer. 22 36 Levels of specific miRNAs in serum or whole blood are stable, reproducible and consistent within species, with no significant differences between healthy males and females for most. 37 36 Published reports of circulating miRNAs in colorectal cancer are limited, however Ng et al. found miR-17-3p and miR-92 were significantly elevated in the serum of colorectal cancer patients with significant reduction following surgery. 38 Further validation with an independent set of 180 samples indicated that miR-92 levels in plasma can distinguish between colorectal and gastric cancers, inflammatory bowel disease or normal subjects. 38 A separate study comparing plasma miRNA expression in 157 patients with advanced adenomas or carcinomas and 59 controls found significant upregulation of miR-29a and miR-92a in colorectal cancer patients.
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MiRNAs in faecal matter
Much of the attention to date has been focussed on miRNAs in tissue and, to a lesser extent, in circulation, however there are some recent reports of detection of miRNAs in stool samples indicating that miRNAs can be extracted from stool in a reproducible and predictable fashion and possibly distinguish between individuals with and without colorectal neoplasia, though this requires further investigation in a larger cohort. 40 41 M A N U S C R I P T
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MiRNAs as tumour markers
It is likely that circulating or faecal miRNAs may present an opportunity to develop new, relatively non-invasive molecular markers of tumour activity. In view of the variability of expression, a tumour-specific profile based on a panel of miRNAs may have greater sensitivity and specificity than use of single miRNAs. 35 42
MiRNAs as prognostic indicators
Current investigations for diagnosis and staging of colorectal cancer are based on histology and radiology. MiRNAs have immense potential to refine this process, providing better information regarding staging and prognosis, and perhaps identifying patients who are likely to respond well to therapy.
MiRNA expression has already been shown to correlate with disease outcomes.
Tumours expressing high levels of miR-21 or miR-200 correlate with poorer prognosis regardless of stage and miR-29a expression is associated with more advanced tumours or positive nodes. 8 43 Patients with stage II colorectal carcinoma with high expression of miR-320 or miR-498 showed significantly shorter progression-free survival. 44 As described previously, miRNAs can also distinguish microsatellite unstable colon cancers from microsatellite stable colon cancers.
MiRNAs and therapeutic response
Tumour response to treatment may be affected by the miRNA expression profile. In one study, high levels of miR-196a promoted chemosensitivity towards platin derivatives. 45 Suppression of miR-31 has recently been shown to increase sensitivity • Insulin receptor substrate-1 (IRS-1)
• C-Myc (oncogenic transcription factor)
• DNA methyltransferase 3A
• Tumour suppressor gene TP53
• Cell cycle regulator Cdc25A
• Bcl-X L oncogene M A N U S C R I P T
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